OncoMatch/Clinical Trials/NCT06431490
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Is NCT06431490 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies TQB2102 for for biliary tract cancer.
Treatment: TQB2102 for — To evaluate the efficacy and safety TQB2102 for injection in the treatment of patients with Her2-positive biliary tract cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (IHC 3+ or IHC 2+ and ISH+)
HER2 expression or amplification or mutation require immunohistochemistry of HER2 3+ or HER2 2 and positive for in situ hybridization (ISH)
Required: HER2 (ERBB2) amplification (IHC 3+ or IHC 2+ and ISH+)
HER2 expression or amplification or mutation require immunohistochemistry of HER2 3+ or HER2 2 and positive for in situ hybridization (ISH)
Required: HER2 (ERBB2) mutation (IHC 3+ or IHC 2+ and ISH+)
HER2 expression or amplification or mutation require immunohistochemistry of HER2 3+ or HER2 2 and positive for in situ hybridization (ISH)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard treatment
Failure of previous standard treatment
Cannot have received: anti-HER2 therapy
Exception: only for the second stage, the first stage is not limited
Have previously received anti-HER2 therapy drugs (only for the second stage, the first stage is not limited)
Lab requirements
Blood counts
The main organs function well
Kidney function
The main organs function well
Liver function
The main organs function well
The main organs function well
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify